ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1654

Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL

Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

Meeting: ACR Convergence 2021

Keywords: American College of Rheumatology Criteria, Anti-citrullinated Protein Autoantibodies (ACPAs), Inflammation, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and older age are not sufficiently covered in the literature.

Comparative study of early RA with onset at young (18-49 years) and older age (50 years and older) before start of DMARDs, biologics and other targeted therapy and glucocorticoids.

Methods: 292 patients with RA were included into the All-Russian register of patients with arthritis “OREL” in the period from January 01, 2012 to December 31, 2018 with research data at the time of the first visit. All patients did not receive DMARDs (synthetic, biological or other targeted drugs) and glucocorticoid systemic therapy before being entered into the registry and were investigated before prescribing DMARDs. 141/292 patients (25 men, 116 women, mean age 39.27 ± 7.97 years, mean duration of disease 5,7±2,75 months) had RA onset at a younger (18-49 years old) age – group 1, 151/292 (men – 41, women – 110, mean age 66.05 ± 7.34 years, mean duration of disease 4,3±3,6 months) had RA onset at senior age (50 years and older) – group 2. RA was diagnosed in accordance with 1987 ACR and 2010 ACR/EULAR criteria. Disease activity was assessed according to DAS-28 index, X-ray stage – according to Steinbrocker, modified stages, functional disorders – in accordance with functional class (FC).

Results: In the group 2, the male / female ratio was higher (1: 2.8) than in the group 1 (1: 4.6) (p=0,055), which indicates a tendency to equalization of the sex ratio with age. Following disorders developed more often in group 2 than group 1: restriction of mobility and morning stiffness (82% vs 59%) (p< 0.05), the frequency of damage to small joints of the hands (76% vs 65%) (p >0.05), wrists (65% vs 52%) (p< 0.05), elbow (33% vs 17%) (p< 0.05), knee (53% vs 36%) (p< 0.05), shoulder (44% vs 19%) (p< 0.05), the total number of affected joints also significantly prevailed in the group 2 (in total cases p< 0,05). Group 2 patients showed stronger and more frequently inflammatory process patients of group 2 comparatively with the Group 1 was (high inflammatory activity - 66% versus 35%, respectively) (p< 0.05), as well as destructive changes (erosive arthritis - 52% versus 29%; p< 0.05) in the joints and functional disorders (FC 3 - 68% versus 15%, respectively) (p< 0.05). Extra-articular manifestations in the form of rheumatoid nodules were more often recorded in the group 2 (10% versus 2%) (p< 0.05). At the same time, ACPAs was not significantly more often detected in group 1 (89% versus 78%) (p > 0.05) with the common frequency of RF detection (72% and 72%).

Conclusion: Comparative study of the clinical characteristics of the natural course of early RA with onset in young adult (18-49 years) and with onset in older (50 years and older) age according to the data of the All-Russian register of patients with arthritis OREL showed that RA with onset in older age is characterized by stronger and more frequently inflammatory process, destructive and functional disorders in the joints than RA with onset at a younger age.


Disclosures: A. Satybaldyev, None; G. Gridneva, None; A. Misiyuk, None; N. Demidova, None; K. Kasumova, None; E. Nasonov, None.

To cite this abstract in AMA style:

Satybaldyev A, Gridneva G, Misiyuk A, Demidova N, Kasumova K, Nasonov E. Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/comparative-characteristics-of-the-natural-course-of-early-rheumatoid-arthritis-with-onset-at-a-young-age-18-49-years-and-older-50-years-and-older-patients-who-did-not-take-dmards-biologics-othe/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-characteristics-of-the-natural-course-of-early-rheumatoid-arthritis-with-onset-at-a-young-age-18-49-years-and-older-50-years-and-older-patients-who-did-not-take-dmards-biologics-othe/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology